435 related articles for article (PubMed ID: 31139691)
1. Neurofilament as a potential biomarker for spinal muscular atrophy.
Darras BT; Crawford TO; Finkel RS; Mercuri E; De Vivo DC; Oskoui M; Tizzano EF; Ryan MM; Muntoni F; Zhao G; Staropoli J; McCampbell A; Petrillo M; Stebbins C; Fradette S; Farwell W; Sumner CJ
Ann Clin Transl Neurol; 2019 May; 6(5):932-944. PubMed ID: 31139691
[TBL] [Abstract][Full Text] [Related]
2. Phosphorylated neurofilament heavy chain in cerebrospinal fluid and plasma as a Nusinersen treatment response marker in childhood-onset SMA individuals from Serbia.
Brkušanin M; Kosać A; Branković-Srećković V; Jovanović K; Perić S; Karanović J; Matijašević Joković S; Garai N; Pešović J; Nikolić D; Stević Z; Brajušković G; Milić-Rašić V; Savić-Pavićević D
Front Neurol; 2024; 15():1394001. PubMed ID: 38756215
[TBL] [Abstract][Full Text] [Related]
3. Full-Length SMN Transcript in Extracellular Vesicles as Biomarker in Individuals with Spinal Muscular Atrophy Type 2 Treated with Nusinersen.
Trifunov S; Natera-de Benito D; Carrera-García L; Codina A; Expósito-Escudero J; Ortez C; Medina J; Torres Alcala S; Bernal S; Alias L; Badosa C; Balsells S; Alcolea D; Nascimento A; Jimenez-Mallebrera C
J Neuromuscul Dis; 2023; 10(4):653-665. PubMed ID: 37038823
[TBL] [Abstract][Full Text] [Related]
4. An Integrated Safety Analysis of Infants and Children with Symptomatic Spinal Muscular Atrophy (SMA) Treated with Nusinersen in Seven Clinical Trials.
Darras BT; Farrar MA; Mercuri E; Finkel RS; Foster R; Hughes SG; Bhan I; Farwell W; Gheuens S
CNS Drugs; 2019 Sep; 33(9):919-932. PubMed ID: 31420846
[TBL] [Abstract][Full Text] [Related]
5. Scientific rationale for a higher dose of nusinersen.
Finkel RS; Ryan MM; Pascual Pascual SI; Day JW; Mercuri E; De Vivo DC; Foster R; Montes J; Gurgel-Giannetti J; MacCannell D; Berger Z
Ann Clin Transl Neurol; 2022 Jun; 9(6):819-829. PubMed ID: 35567345
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the neurofilament light chain as a biomarker in children with spinal muscular atrophy treated with nusinersen.
Seo G; Kim S; Byun JC; Kwon S; Lee YJ
Brain Dev; 2023 Nov; 45(10):554-563. PubMed ID: 37541812
[TBL] [Abstract][Full Text] [Related]
7. Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children.
Nitz E; Smitka M; Schallner J; Akgün K; Ziemssen T; von der Hagen M; Tüngler V
Ann Clin Transl Neurol; 2021 Oct; 8(10):2013-2024. PubMed ID: 34482646
[TBL] [Abstract][Full Text] [Related]
8. Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.
Dabbous O; Maru B; Jansen JP; Lorenzi M; Cloutier M; Guérin A; Pivneva I; Wu EQ; Arjunji R; Feltner D; Sproule DM
Adv Ther; 2019 May; 36(5):1164-1176. PubMed ID: 30879249
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of putative CSF biomarkers in paediatric spinal muscular atrophy (SMA) patients before and during treatment with nusinersen.
Johannsen J; Weiss D; Daubmann A; Schmitz L; Denecke J
J Cell Mol Med; 2021 Sep; 25(17):8419-8431. PubMed ID: 34312963
[TBL] [Abstract][Full Text] [Related]
10. Neurodegeneration Biomarkers in Adult Spinal Muscular Atrophy (SMA) Patients Treated with Nusinersen.
Andrés-Benito P; Vázquez-Costa JF; Ñungo Garzón NC; Colomina MJ; Marco C; González L; Terrafeta C; Domínguez R; Ferrer I; Povedano M
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612621
[TBL] [Abstract][Full Text] [Related]
11. A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen.
Paris A; Bora P; Parolo S; MacCannell D; Monine M; van der Munnik N; Tong X; Eraly S; Berger Z; Graham D; Ferguson T; Domenici E; Nestorov I; Marchetti L
CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):196-206. PubMed ID: 36471456
[TBL] [Abstract][Full Text] [Related]
12. Neurofilament Levels in CSF and Serum in an Adult SMA Cohort Treated with Nusinersen.
Rich KA; Fox A; Yalvac M; Heintzman S; Tellez M; Bartlett A; Severyn S; Linsenmayer M; Kelly K; Reynolds J; Sterling GB; Weaver T; Rajneesh K; Pino MG; Arnold WD; Elsheikh B; Kolb SJ
J Neuromuscul Dis; 2022; 9(1):111-119. PubMed ID: 34776417
[TBL] [Abstract][Full Text] [Related]
13. Nusinersen treatment and cerebrospinal fluid neurofilaments: An explorative study on Spinal Muscular Atrophy type 3 patients.
Faravelli I; Meneri M; Saccomanno D; Velardo D; Abati E; Gagliardi D; Parente V; Petrozzi L; Ronchi D; Stocchetti N; Calderini E; D'Angelo G; Chidini G; Prandi E; Ricci G; Siciliano G; Bresolin N; Comi GP; Corti S; Magri F; Govoni A
J Cell Mol Med; 2020 Mar; 24(5):3034-3039. PubMed ID: 32032473
[TBL] [Abstract][Full Text] [Related]
14. Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy.
Schorling DC; Kölbel H; Hentschel A; Pechmann A; Meyer N; Wirth B; Rombo R; ; Sickmann A; Kirschner J; Schara-Schmidt U; Lochmüller H; Roos A
Eur J Neurol; 2022 Jul; 29(7):2084-2096. PubMed ID: 35318785
[TBL] [Abstract][Full Text] [Related]
15. Children and young adults with spinal muscular atrophy treated with nusinersen.
Osredkar D; Jílková M; Butenko T; Loboda T; Golli T; Fuchsová P; Rohlenová M; Haberlova J
Eur J Paediatr Neurol; 2021 Jan; 30():1-8. PubMed ID: 33307321
[TBL] [Abstract][Full Text] [Related]
16. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS; Mercuri E; Darras BT; Connolly AM; Kuntz NL; Kirschner J; Chiriboga CA; Saito K; Servais L; Tizzano E; Topaloglu H; Tulinius M; Montes J; Glanzman AM; Bishop K; Zhong ZJ; Gheuens S; Bennett CF; Schneider E; Farwell W; De Vivo DC;
N Engl J Med; 2017 Nov; 377(18):1723-1732. PubMed ID: 29091570
[TBL] [Abstract][Full Text] [Related]
17. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
[TBL] [Abstract][Full Text] [Related]
18. Neurofilament light protein as a biomarker for spinal muscular atrophy: a review and reference ranges.
Bayoumy S; Verberk IMW; Vermunt L; Willemse E; den Dulk B; van der Ploeg AT; Pajkrt D; Nitz E; van den Hout JMP; van der Post J; Wolf NI; Beerepoot S; Groen EJN; Tüngler V; Teunissen CE
Clin Chem Lab Med; 2024 Jun; 62(7):1252-1265. PubMed ID: 38215341
[TBL] [Abstract][Full Text] [Related]
19. Serum Phosphorylated Neurofilament-Heavy Chain, a Potential Biomarker, is Associated With Peripheral Neuropathy in Patients With Type 2 Diabetes.
Qiao X; Zhang S; Zhao W; Ye H; Yang Y; Zhang Z; Miao Q; Hu R; Li Y; Lu B
Medicine (Baltimore); 2015 Nov; 94(44):e1908. PubMed ID: 26554790
[TBL] [Abstract][Full Text] [Related]
20. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
